Institutional members access full text with Ovid®

The Role of Bacterial Biofilm in Adverse Soft-Tissue Filler Reactions: A Combined Laboratory and Clinical Study

Saththianathan, Mayuran B.H.B., M.B.Ch.B., M.S.; Johani, Khalid B.Sc.; Taylor, Alaina M.B.B.S.; Hu, Hongua Ph.D.; Vickery, Karen B.V.Sc., Ph.D.; Callan, Peter F.R.A.C.S.; Deva, Anand K. M.S., B.Sc.(Med.), F.R.A.C.S.

Plastic & Reconstructive Surgery: March 2017 - Volume 139 - Issue 3 - p 613–621
doi: 10.1097/PRS.0000000000003067
Experimental: Original Articles
Discussion

Background: The development of chronic nodules and granulomatous inflammation after filler injections has been attributed to bacterial biofilm infection. The authors aimed to investigate the relationship between filler and bacterial biofilm using a combined in vitro and in vivo study.

Methods: In vitro assays to investigate the ability of filler materials to support the growth of Staphylococcus epidermidis biofilm and the effect of multiple needle passes through a biofilm-contaminated surface were designed. Analysis of clinical biopsy specimens from patients presenting with chronic granulomas following filler administration using a number of laboratory tests for biofilm was performed.

Results: All fillers (i.e., hyaluronic acid, polyacrylamide gel, and poly-L-lactic acid) supported the growth of S. epidermidis biofilm in vitro. Multiple needle passes through a biofilm-contaminated surface resulted in significantly increased contamination of filler material by a factor of 10,000 (p < 0.001). Six clinical samples from five patients all demonstrated bacterial biofilm. The mean number of bacteria was found to be 2.2 × 107 bacteria/mg tissue (range, 5.6 × 105 to 3.7 × 107 bacteria/mg tissue). Microbiome analysis detected a predominance of Pseudomonas, Staphylococcus, and Propionibacterium as present in these samples.

Conclusions: Filler material can support the growth of bacterial biofilm in vitro. Multiple needle passes can significantly increase the risk of filler contamination. Biofilm appears to be associated with high numbers in clinical samples of patients presenting with chronic granulomatous inflammation. Strategies to reduce the risk of bacterial contamination need to be further studied and translated into clinical practice.

CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V.

Sydney, New South Wales, and Melbourne, Victoria, Australia

From the Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University; and the University of Melbourne.

Received for publication April 6, 2016; accepted July 25, 2016.

Disclosure: Prof. Deva and Prof. Vickery are consultants to Allergan, Mentor (J&J), and KCI. They have previously coordinated industry-sponsored research for these companies relating to both biofilms and breast prostheses. Dr. Callan is a consultant to Allergan.

Anand K. Deva, B.Sc.(Med.), M.S., F.R.A.C.S., Suite 33/20-24, Gibbs Street, Miranda, New South Wales 2228, Australia, anand.deva@mq.edu.au

©2017American Society of Plastic Surgeons